Daily Compliance News: August 13, 2025. The Bad App Store Ratings Edition
Daily Compliance News: April 17, 2025, The Musk Fights BEE's Edition
Law Brief®: Rich Schoenstein and Robert Heim Discuss Musk v. Twitter
The Woody Report - Twitter v. Elon Musk
SPECIAL EDITION: NEWS + VIEWS + TO DO’S | ERIN HIGGINS, CONN KAVANAUGH
Everything Compliance - The Elon Etc Edition
Compliance Into The Weeds - Musk Pulls U-Turn on Twitter Board
FCPA Compliance Report - Karen Woody on Elon Musk Attack on SEC Consent Decree
Compliance Into The Weeds - Elon Musk and Tesla Redux
This Week in FCPA-Episode 252 – the Musk and Bitcoin edition
Compliance into the Weeds-Elon Musk, Cryptocurrency and the SEC
Top Five Corporate Scandals of 2018: Episode IV-Tesla and its Elon Problem
This Week in FCPA-Episode 122, the Kavanaugh, Rosenstein and 100+ Wins edition
The FDA began integration of generative AI across all its centers, a project that should be completed by the end of June. Newly appointed chief AI officer, Jeremy Walsh, and Office of Strategic Programs at CDER, Sridhar...more
Neuralink, the biotechnology company founded by Elon Musk, has received approval from the U.S. Food and Drug Administration (FDA) to commence human trials of its implantable brain-computer interface device. Recruitment for...more
More detail is emerging on the DOJ’s ongoing antitrust probe into Google, with recent attention to the company’s online ad tools suggesting the topic has become “a major focus of the investigation,” with special focus on “how...more
Opioid manufacturer Insys Therapeutics, which just last week agreed to pay $225 million to “settle a federal investigation into the marketing practices for its powerful fentanyl painkiller,” has filed for bankruptcy...more
Jobs report Friday again. Which, after February’s dismal numbers, is carrying extra importance today. We’ll be keeping an eye on US manufacturing, among other things. Here’s what to watch....more
GE—still in streamlining mode—agreed yesterday to sell its biopharma business to Danaher (current CEO Larry’s Culp’s former company, btw) for a reported $21.4 billion in the form of $21 billion in cash and $400 million in...more
Takeda has officially emerged victorious in the battle for Shire. The Japanese drug giant will pay more than $66/share to acquire Shire in a deal valued at $62 billion....more
The Fed’s Open Markets Committee meets today, and despite relatively robust economic numbers of late, the lack of oped-for inflation (among other things) is likely to keep the Fed from moving on interest rates again at this...more